Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Supaglutide

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)

Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 2/3 · Completed · Enrollment 547

NCT04994288

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Supaglutide RP3D high dosen/rn/rn/rn/r
supaglutide RD3D Low dosen/rn/rn/rn/r
placebon/rn/rn/rn/r

Not shown

  • Supaglutide RP3D high dose: endpoint not reported
  • supaglutide RD3D Low dose: endpoint not reported
  • placebo: endpoint not reported